Welcome to the June 2026 issue of Clinical Thyroidology. As we come to the sixth issue of the year, it is good time to reflect on the first half of the year and to see what is ahead. Moving to Sage, our new publisher, brings a new look to the website and new opportunities for promoting and enhancing the journal. I look forward to opportunities to receive this journal in new and exciting ways. We have also released several reviews of the 2025 ATA Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. There is a lot to unpack with these guidelines, and we will continue to tackle different aspects as we go through the year.
So, without further ado, what is there to see this month?
We begin with thyroid cancer. In “2025 ATA Guidelines: The Critical Role of Local Therapy Rather than Initial Systemic Therapy,” Dr. Fernanda Vaisman examines updated ATA guidance emphasizing the importance of local treatment approaches in select patients with metastatic disease. In “ITOG 2026 Annual Meeting Summary—Driving Progress toward a Cure of Advanced Thyroid Cancer,” Dr. Mara V. Roth, Dr. Terrence Williams, Dr. Sasan Fazeli, and Dr. Laura Boucai review highlights from the annual ITOG meeting and discuss advances shaping the future of care for advanced thyroid cancer. Then, in “Feasibility of Active Surveillance for Locoregional Recurrent Differentiated Thyroid Cancer,” Dr. Simone de Leo explores emerging evidence supporting active surveillance strategies in carefully selected patients with recurrent disease.
We next turn to thyroid nodules. In “Elastography for Thyroid Nodule Risk Stratification: Does It Add Value beyond TI-RADS?” Dr. Elizabeth Cottrill evaluates whether elastography meaningfully improves ultrasound-based risk assessment. Relatedly, in “Which Ultrasound Risk-Stratification System Performs Best? A Comparison of Five Leading Systems,” Dr. Eyal Robenshtok compares the diagnostic performance of several widely used thyroid nodule classification systems.
A pair of reviews on thyroid function follow. The first on hyperthyroidism features “Autoimmunity Amplified: Graves’ Disease in the Era of Immune Checkpoint Inhibitors,” in which Dr. Thatiana Schulze Goni and Dr. Natalie Genere review the adverse thyroid outcomes in patients with preexisting Graves’ disease who receive cancer immunotherapy. In hypothyroidism, “TSH Targets in the Elderly—New Data from the Largest Observational Study So Far,” by Dr. Joris Osinga, reviews important new findings regarding optimal TSH targets in older adults.
We then move to thyroid eye disease with “Beyond Orbital Improvement: The Metabolic Shadow of Teprotumumab,” where Dr. Yedi Cao and Dr. Ying Gao discuss data showing a worrisome degree and persistence of hyperglycemia in patients treated with teprotumumab.
Finally, we conclude with pediatric thyroidology. In “Risk of Developing Thyroid Abnormalities in Children Treated for High-Risk Neuroblastoma,” Dr. Christine Cherella examines the long-term thyroid consequences faced by survivors of high-risk neuroblastoma treatment.
It is an issue full of exciting new data and insightful perspectives. All are welcome to join us on social media, where we highlight content from each month’s issue to foster greater dialogue and discussion about the latest clinical thyroid literature and other topics related to thyroid health and disorders. Clinical Thyroidology is found at:
As always, we extend a thank you to the editorial board of Clinical Thyroidology for the Public (CTFP), led by Dr. Alan Farwell, for providing freely available lay summaries of our Clinical Thyroidology articles each month, which makes this content accessible to patients and the general public who are interested in learning more about recently published studies in the clinical thyroid literature. CTFP can be found online at https://www.thyroid.org/patient-thyroid-information/ct-for-patients.
I welcome your questions, suggestions, or comments at clinicalthyroidology@thyroid.org.
Please visit the Clinical Thyroidology website to see present and past articles, and enjoy reading.
